HITS, the KAIST spinout, has raised $13.4M to put AI agents that search literature, analyze data and test hypotheses into…
Massive Bio has appointed a Seoul-based partner to grow its AI clinical trial matching business in Korea, where it has…
Seoul St. Mary's Hospital built in-house AI that screens myeloma patients for trial eligibility in seconds.
KAIST's homegrown K-Fold model predicts protein-drug binding structures up to 25 times faster than existing AI.
KT and Seoul National University Hospital team up on a shared AI platform for public healthcare.